Bishop et al. also demonstrated that an IKKe/TRAF6 (downstream target of IL-1) inhibitor could reduce osteoclastic bone destruction from 4T1 tumours growing in the bone; however, this treatment did not significantly reduce the percentage of mice that developed bone metastases [28,29]. The gene discussed is TRAF6; the disease is neoplasm.